AIDS in Africa: The impact of coinfections on the pathogenesis of HIV-1 infection

Journal of Infection

Volumn 48, Issue 1, 2004, Pages 1-12

  Lawn, Steve D ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Africa; AIDS; Coinfections; Disease progression; HIV 1; Immune activation; Pathogenesis; Viral load

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AFRICA SOUTH OF THE SAHARA; CELL ACTIVATION; CELL LOSS; COMORBIDITY; DATA ANALYSIS; DISEASE COURSE; EPIDEMIC; GENETIC HETEROGENEITY; GENITAL ULCER; GENOTYPE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFECTION RISK; LIFE CYCLE; MALARIA; PATHOGENESIS; PHYSIOLOGY; RECURRENT INFECTION; RETROSPECTIVE STUDY; REVIEW; SCHISTOSOMIASIS; SUPERINFECTION; TUBERCULOSIS; VIRUS CELL INTERACTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0346656812     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2003.09.001     Document Type: Review

References (87)

1. UNAIDS/WHO. AIDS epidemic update. December 2002 www.unaids.org/worldaidsday/2002/press/Epiupdate.html Accessed June 12, 2002.
2. WHO. World Health Report, Health Systems: Improving Performance. Geneva: WHO; 2000.
3. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001;14:753-777.
4. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV1 transmission and disease progression. Nat Med 1996;2:1240-1243.
5. Kirchoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 1995;332:228-232.
6. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996;12:585-592.
7. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. Immunol Today 1995;16:187-191.
8. Blanchard A, Montagnier L, Gougeon M-L. Influence of microbial infections on the progression of HIV disease. Trends Microbiol 1997;5:326-331.
9. Wahl SM, Greenwell-Wild T, Peng G, et al. Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression. Proc Natl Acad Sci USA 1998;95: 12574-12579.
10. Juffermans NP, Speelman P, Verbon A, et al. Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells. Clin Infect Dis 2001;32:650-652.
11. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61: 213-222.
12. Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell 1998;95:595-604.
13. Gaynor R. Cellular transcription factors involved in the regulation of HIV-1 gene expression. AIDS 1992;6:347-363.
14. Baeuerte PA. The inducible transcription activator NF-kappa B: regulation by distinct protein subunits. Biochim Biophys Acta 1991;1072:63-80.
15. Tong-Starksen SE, Welsh TM, Peterlin BM. Differences in transcriptional enhancers of HIV-1 and HIV-2. Response to T cell activation signals. J Immunol 1990;145:4348-4354.
16. De Cock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA 1993;270:2083-2086.
17. Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol 1997;71:8657-8665.
18. Gendelman HE, Phelps W, Feigenbaum L, et al. Transactivation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses. Proc Natl Acad Sci USA 1986;83:9759-9763.
19. Clerici M, Shearer GM. A Th1 to Th2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993;107: 107-111.
20. Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994;265:244-248.
21. Graziosi C, Pantaleo G, Gantt KR, et al. Lack of evidence for the dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 1994;265:248-252.
22. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992;257:217-219.
23. Mancino G, Placido R, Bach S, et al. Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells. J Infect Dis 1997;175:1531-1535.
24. Mann DL, Gartner S, Le Sane F, Buchow H, Popovic M. HIV-1 transmission and function of virus-infected monocytes/macrophages. J Immunol 1990;144:2152-2158.
25. Tsunetsugu-Yokota Y, Akagawa K, Kimoto H, et al. Monocyte-derived cultured dendritic cells are susceptible to human immunodeficiency virus infection and transmit virus to resting T cells in the process of nominal antigen presentation. J Virol 1995;69:4544-4547.
26. Soudeyns H, Paolucci S, Chappey C, et al. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. Eur J Immunol 1999;29:3629-3635.
27. Ostrowski MA, Justement SJ, Catanzaro A, et al. Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals. J Immunol 1998;161: 3195-3201.
28. Collins KR, Quinones-Mateu ME, Wu M, et al. Human immunodeficiency virus type 1 (HIV-1) quasispecies at the sites of Mycobacterium tuberculosis infection contribute to systemic HIV-1 heterogeneity. J Virol 2002;76:1697-1706.
29. 2-microglobutin, respectively. Clin Exp Immunol 2000;122:79-84.
30. Vanham G, Edmonds K, Qing L, et al. Generalised immune activation in pulmonary tuberculosis: coactivation with HIV infection. Clin Exp Immunol 1996;103:30-34.
31. Lederman MM, Georges DL, Kusner DJ, Mudido P, Giam C-Z, Toossi Z. Mycobacterium tuberculosis and its purified protein derivative activate expression of human immunodeficiency virus. J Acquir Immune Defic Syndr 1991;7:727-733.
32. Shattock RJ, Friedland JS, Griffin GE. Phagocytosis of Mycobacterium tuberculosis modulates human immunodeficiency virus replication in human moncytic cells. Res Virol 1994;75:849-856.
33. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication. Rote of immune activation. J Immunol 1996;157:1271-1278.
34. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol 2001;123:233-238.
35. Whalen C, Horsbrough CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of HIV infection after tuberculosis. Am J Respir Care Med 1995;151:129-135.
36. Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000;14:1219-1228.
37. Del Amo J, Malin AS, Pozniak A, De Cock KM. Does tuberculosis accelerate the progression of HIV disease? Evidence from basic science and epidemiology. AIDS 1999; 13:1151-1158.
38. Lawn SD, Pisell TL, Hirsch CS, Wu M, Butera ST, Toossi Z. Anatomically compartmentalized human immunodeficiency virus replication in HLA-DR + cells and CD14 + macrophages at the site of pleural tuberculosis coinfection. J Infect Dis 2001;184:1127-1133.
39. Toossi Z, Johnson JL, Kanost RA, et al. Increased replication of HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. J Acquir Immune Defic Syndr 2001;28:1-8.
40. Nakata K, Rom W, Honda Y, et al. M. tuberculosis enhances HIV-1 replication in the lung. Am J Respir Crit Care Med 1997;155:996-1003.
41. Morris L, Silber E, Sonnenberg P, et al. High human immunodeficiency virus type 1 RNA load in the cerebrospinal. fluid from patients with lymphocytic meningitis. J Infect Dis 1998;177:473-476.
42. Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of human immunodeficiency virus type 1 infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes Infect 2002;4:635-646.
43. Lawn SD, Labeta MO, Arias M, Acheampong JW, Griffin GE. Elevated serum concentrations of soluble CD14 in HIV-negative and HIV-positive patients with tuberculosis in Africa: prolonged elevation during antituberculosis treatment. Clin Exp Immunol 2000;120:483-487.
44. Lawn SD, Rudolph D, Coulibaly D, Ackah A, Wiktor S, Lal RB. Lack of induction of interleukin-2-receptor alpha expression in patients with tuberculosis and human immunodeficiency virus coinfection: implications for pathogenesis. Trans R Soc Trop Med Hyg 2001;95:449-452.
45. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997;276: 1857-1861.
46. Tremblay MJ, Fortin J-F, Cantin R. The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998;19: 346-351.
47. Lawn SD, Roberts BD, Griffin GE, Folks TM, Butera ST. Cellular compartments of HIV1 replication: determination by virion-associated host proteins and the impact of opportunistic infection in vivo. J Virol 2000;74:139-145.
48. Perelson AS, Neumann A, Markowitz M, Leonard JM, Ho DD. HIV1 dynamics in vivo: virion clearance rate, infected cell tife-span, and viral generation time. Science 1996;271: 1582-1586.
49. Lawn SD, Butera ST. Incorporation of HLA-DR into the HIV-1 envelope: correlation with stage of disease and the effect of opportunistic infection in vivo. J Virol 2000;74: 10256-10259.
50. Lawn SD, Shattock RJ, Acheampong JW, Lal RB, Folks TM, Griffin GE, Butera ST. Sustained plasma TNF-α and HIV-1 load despite resolution of other immune activation parameters during treatment for tuberculosis in Africans. AIDS 1999;13: 2231-2237.
51. Cantin R, Fortin J-F, Lamontagne G, Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol 1997; 71:1922-1930.
52. Sulkowski MS, Chaisson RE, Karp CL, Moore RD, Margolick JB, Quinn TC. The effect of acute infectious illnesses on plasma human immunodeficiency virus type I load and the expression of serologic markers of immune activation among HIV-infected adults. J Infect Dis 1998;178: 1642-1648.
53. Wallis RS, Nsubuga P, Whalen C, et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727-733.
54. Morris L, Martin DJ, Sacks L, et al. Persistent elevation of HIV load during treatment for tuberculosis. Abstracts of Fifth Conference on Retroviruses and Opportunistic Diseases. Chicago, 1998 [abstract 259].
55. Rizzardini G, Piconi S, Ruzzante S, et al. Immunological activation markers in the serum of African and European HIV-positive and seronegative individuals. AIDS 1996;10: 1535-1542.
56. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, Strannegard O. Raised levels of tumour necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin Exp Immunol 1993;91:37-42.
57. Chan MS, Medley GF, Jamison D, Bunday DA. The evaluation of potential morbidity attributable to intestinal nematode infections. Parasitology 1994;109:373-387.
58. World malaria situation in 1994, Part III. Wkly Epidemiol Rec 1997;72:285-290.
59. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium folciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999;13:487-494.
60. Pisell T, Hoffman IF, Jere CS, et al. Immune activation and induction of HIV-1 replication within CD14 + macrophages during acute Plasmodium falciparum malaria coinfection. AIDS 2002;16:1503-1509.
61. Freitag C, Chougnet C, Schito M, et al. Malaria infection induces virus expression in human immunodeficiency virus transgenic mice by CD4 T-cell dependent immune activation. J Infect Dis 2001;183:1260-1268.
62. Kublin JG, Jere CS, Miller WC, et al. Malaria infection elevates HIV-1 viral load. Abstracts of the XIV International AIDS Conference Barcelona 2002, Abstract #1375.
63. Pearce EJ, Caspar P, Grzych J-M, Lewis FA, Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991;173:159-166.
64. Sabin EA, Araujo MI, Carvalho EM, Pearce EJ. Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni. J Infect Dis 1996;173:269-272.
65. Actor JK, Shirai M, Kullberg MC, Mark R, Butter L, Sher A. Helminth infection results in decreased virus-specific CD8 + cytotoxic T-cell responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993;90:948-952.
66. Lawn SD, Karanja DMS, Mwinzi P, et al. The effect of treatment of schistosomiasis on blood plasma HIV-1 RNA concentration in coinfected individuals. AIDS 2000;14: 2437-2443.
67. Wolday D, Mayaan S, Mariam ZG, et al. Treatment of intestinal worms is associated with decreased HIV plasma viral load. J Acquir Immun Defic Syndr 2002;31:56-62.
68. + T cell count, viral load and cytokine responses in HIV-infected Ugandan adults. Trans R Soc Trop Med Hyg 2003;97:103-108.
69. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000;42: 921-929.
70. Royce RA, Sena A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072-1078.
71. Wasserheit JN. Epidemiological synergy: relationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
72. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997;349:1868-1873.
73. Moss GB, Overbaugh J, Welch M, et al. Human immunodeficiency virus DNA in urethral secretions in men: association with gonococcal urethritis and CD4 cell depletion. J Infect Dis 1995;172:1469-1474.
74. Ghys PD, Fransen K, Diallo MO, et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote D'Iviore. AIDS 1997;11:F85-F93.
75. Kreiss J, Willerford DM, Hensel M, et al. Association between cervical inflammation and cervical shedding of human immunodeficiency virus DNA. J Infect Dis 1994;170: 1597-1601.
76. Lawn SD, Subbarao S, Wright TC, et al. Correlation between HIV-1 RNA levels in the female genital tract and immune activation resulting from ulceration of the cervix. J Infect Dis 2000;181:1950-1956.
77. Mellors JW, Rinaldo Jr. CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
78. Colebunders R, Ryder R, Francis H, et al. Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. J Infect Dis 1991;164: 450-456.
79. Whittle H, Egboga A, Todd J, et al. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-1 infection. AIDS 1992;6:685-689.
80. N'Galy B, Ryder RW, Bila K. Human immunodeficiency virus infection among employees in an African hospital. N Engl J Med 1988;319:1123-1127.
81. Anzala OA, Nagelkerke NJD, Bwayo JJ, et al. Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection. J Infect Dis 1995; 171:686-689.
82. Taha TE, Graham SM, Kumwenda NI, et al. Morbidity among human immunodeficiency virus-1-infected and -uninfected African children. Pediatrics 2000;106:e77.
83. Morgan D, Maude GH, Malamba SS, et al. HIV-1 disease progression and AIDS-defining disorders in rural Uganda. Lancet 1997;350:245-250.
84. Morgan D, Whitworth JAG. The natural history of HIV-1 infection in Africa. Nat Med 2001;7:143-145.
85. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999;353:1469-1475.
86. Del Amo J, Malin AS, Pozniak A, De Cock KM. Does tuberculosis accelerate the progresson of HIV disease? Evidence from basic science and epidemiology. AIDS 1999; 13:1151-1158.
87. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998;317:625-629.